Kardigan plans $320M IPO for heart drugs as Nasdaq listings gain steam

Tassos Gianakakos, Kardigan CEO June 11, 2026 09:32 AM EDT DealsIPOs Kardi­gan's $320M IPO pitch: Three bor­rowed heart drugs, one proven car­dio CEO Kyle LaHucik Biotech Correspondent Para­bilis Med­i­cines’ record-break­ing IPO will be a tough act to fol­low, but a drug de­vel­op­er with three late-stage car­dio med­i­cines is up … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER